Evidence to Support the Collaboration of SP1, MYC, and HIF1A and Their Association with microRNAs

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
• Targeting cancer stem cell pathways is a promising therapeutic strategy.
• Previous research suggests SP1, MYC, and HIF1A are crucial in cancer progression.

Purpose of the Study:

• To investigate the potential of inhibiting SP1, MYC, and HIF1A to induce anticancer activity in glioblastoma.
• To evaluate the efficacy of combined M4N and A4N treatments on glioblastoma stem cell markers and cell death.

Main Methods:

• Treatment of LN229 and U87MG glioblastoma cells with M4N and A4N, individually and in combination.
• Assessment of SP1, MYC, HIF1A, and stem cell-related protein expression.
• Quantification of cell death.
• Bioinformatic analysis of protein-protein interactions and microRNA associations.

Main Results:

• Individual M4N or A4N treatments showed limited suppression of SP1 and stem cell proteins, with minimal cell death.
• Combination treatment with M4N and A4N significantly suppressed SP1, MYC, and HIF1A expression.
• Combined treatment also greatly reduced all examined stem cell-related proteins and induced significant glioblastoma cell death.
• Bioinformatic analysis revealed SP1, MYC, and HIF1A are involved in transcriptional regulation and associated with cancer-related microRNAs.

Conclusions:

• The combined inhibition of SP1, MYC, and HIF1A demonstrates potent anticancer activity against glioblastoma.
• This strategy effectively reduces cancer stem cell markers and induces significant cell death.
• Targeting SP1, MYC, and HIF1A offers a promising approach for glioblastoma treatment by modulating RNA transcription.